Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

University of Toronto

$165,000.00

What comes next? Uptake of cancer risk reduction strategies by women who receive inconclusive results from BRCA1 and BRCA2 testing

EF 2018-19

Résumé
Breast cancer is the most commonly diagnosed cancer and the 2nd leading cause of cancer death for women in Canada. 20% of familial forms of breast cancer are due to genetic mutations, most commonly in the BRCA1 and BRCA2 genes. When a risk-increasing mutation is identified in these genes, women are eligible for risk reduction strategies such as yearly breast cancer screening with MRI and mammography and/or preventive surgery. However, many women who are tested do not receive a definitive result as to whether they carry a genetic predisposition to cancer; instead, many receive inconclusive results (a mutation with uncertain cancer risk is identified or no BRCA mutation is identified but a mutation may exist in an untested gene). For these women, cancer risk is harder to predict. Although no previous studies have shown a benefit to risk-reduction strategies for women with inconclusive results, current guidelines are vague about the need for further treatment. It is, therefore, likely that recommendations made to these women vary by treating physician. The goal of this study is to examine how frequently women who receive inconclusive results from BRCA testing undertake risk reducing strategies. Specifically, we will use a unique data platform that brings together genetic testing and health care utilization information for close to 17,000 women who underwent BRCA testing in Ontario from 2007 to 2016. We will determine factors that influence the use of screening and preventive surgery, including the role of an inconclusive test result. In examining how often these strategies are used, we will identify targets for patients and healthcare provider education around genetic test interpretation and risk reduction. As direct-to-consumer genetic testing becomes more readily available, accurate genetic test interpretation will be increasingly important as both patients and physicians will be faced with the challenge of how to manage an inconclusive genetic test result.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
397019
Name
Dossa Fahima
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Health Research Training B - HP
Projecttitle
What comes next? Uptake of cancer risk reduction strategies by women who receive inconclusive results from BRCA1 and BRCA2 testing
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$165,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Breast Cancer; Genetics; Health Services; Hereditary; Oncology; Screening; Surgery
Abstract
Breast cancer is the most commonly diagnosed cancer and the 2nd leading cause of cancer death for women in Canada. 20% of familial forms of breast cancer are due to genetic mutations, most commonly in the BRCA1 and BRCA2 genes. When a risk-increasing mutation is identified in these genes, women are eligible for risk reduction strategies such as yearly breast cancer screening with MRI and mammography and/or preventive surgery. However, many women who are tested do not receive a definitive result as to whether they carry a genetic predisposition to cancer; instead, many receive inconclusive results (a mutation with uncertain cancer risk is identified or no BRCA mutation is identified but a mutation may exist in an untested gene). For these women, cancer risk is harder to predict. Although no previous studies have shown a benefit to risk-reduction strategies for women with inconclusive results, current guidelines are vague about the need for further treatment. It is, therefore, likely that recommendations made to these women vary by treating physician. The goal of this study is to examine how frequently women who receive inconclusive results from BRCA testing undertake risk reducing strategies. Specifically, we will use a unique data platform that brings together genetic testing and health care utilization information for close to 17,000 women who underwent BRCA testing in Ontario from 2007 to 2016. We will determine factors that influence the use of screening and preventive surgery, including the role of an inconclusive test result. In examining how often these strategies are used, we will identify targets for patients and healthcare provider education around genetic test interpretation and risk reduction. As direct-to-consumer genetic testing becomes more readily available, accurate genetic test interpretation will be increasingly important as both patients and physicians will be faced with the challenge of how to manage an inconclusive genetic test result.
Competitiondate
201811
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Dossa, Fahima
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $165,000~ $0~